Connect with us

Technology

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Published

on

Co-founded by world leading dermatology experts and Medicxi Merger of six asset-centric companies to form a new R&D-centric multi-platform pipeline in immuno-dermatology to harness cutting edge-science and technologiesVision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet need

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ — Alys Pharmaceuticals, Inc. (“Alys”), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi. Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.

Co-founded by Medicxi and several world leading dermatology and scientific experts, including John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Nobel Prize winner Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology), Alys aspires to redefine the landscape of dermatological treatments. The Company is run by co-founder and COO Thibaud Portal (formerly Galderma’s Global Head of Prescription Medicines) and Medicxi’s Francesco De Rubertis serves as Chairman of the Board.

Alys believes that emerging indications such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria, will see the next breakthroughs in dermatological advancements. The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.

Alys is working with leading institutions such as Institut Gustave Roussy, UMass Chan Medical School, Icahn School of Medicine at Mount Sinai, Georgia Institute of Technology and Empa, the Swiss Federal Laboratories for Materials Science & Technology, demonstrating its commitment to collaborative research and development.

Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. With more than a dozen active programs, Alys anticipates further organic pipeline growth from its cutting-edge platforms, covering inflammatory diseases, autoimmune diseases, dermatology supportive care for cancer patients and rare dermatoses. Over the next three years, the company aims to deliver between seven to ten clinical Proof-of-Concept (POC) readouts, and potentially at least one program to advance to registrational studies.

Francesco De Rubertis, Chairman of Alys Pharmaceuticals and Partner at Medicxi commented: “We believe that bringing together several asset-centric companies with a phenomenal team will power up Alys to transform innovation in immuno-dermatology. Alys manages a broad pipeline of assets with diverse risk profiles and will hugely benefit from this change of scale and facilitated access to capital.”

Professor John Harris, Chief Innovation Officer of Alys Pharmaceuticals and Chair of Dermatology at UMass Chan Medical School, added: “It is uniquely exciting to oversee such a rich and diverse pipeline, bringing forward modalities that will break new ground in dermatology, including peptides, sophisticated antibodies, or vectorized siRNA.”

Professor Brian Kim, Vice Chair of Research in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, added: “With its diverse pipeline, Alys’ commitment to advancing the frontiers of immuno-dermatology has the potential to bring transformative solutions to patients worldwide.”

About Alys Pharmaceuticals

Alys Pharmaceuticals, Inc. (“Alys”) is a Boston and Geneva-based cutting edge pure-play immuno-dermatology company. Alys is backed by international investment firm Medicxi with $100M financing. Alys has a world class leadership team that brings together experts across dermatology and advanced scientific fields, including co-founders Craig Mello (UMass Chan Medical School), John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology). Alys is led by dermatology specialist, co-founder and COO Thibaud Portal

It was formed from the aggregation of 6 asset-centric Medicxi companies – Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. Its pipeline boasts 14 active programs, targeting multiple dermatological indications, including atopic dermatitis, vitiligo, psoriasis and mastocytosis. For further information, please visit www.alyspharma.com.  

About Medicxi

Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need. For more information, please visit: www.medicxi.com.

COI Statement

Mount Sinai and Brian Kim, UMass Chan Medical School, Craig Mello and John Harris, Georgia Institute of Technology and Mark Prausnitz, Gustave Roussy and Eric Deutsch, Lars French have financial interests in Alys.

 

View original content:https://www.prnewswire.co.uk/news-releases/alys-pharmaceuticals-launches-with-100m-financing-from-medicxi-to-advance-immuno-dermatology-focused-pipeline-302059125.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Greenzie releases 2025 Annual Safety Report, documenting multi-year safety performance at commercial scale

Published

on

By

The data shows zero lost-time injuries, zero OSHA medical attentions and zero human near-misses across real-world operation

ATLANTA, April 23, 2026 /PRNewswire/ — Greenzie, the technology platform powering commercial autonomy across multiple OEMs, today shared multi-year safety data from real-world commercial operation, documenting more than 150,000 autonomous miles with zero lost-time injuries, zero OSHA medical attentions and zero human near-misses. The data is published in Greenzie’s 2025 Annual Safety Report, available at greenzie.com/safety.

The report is based on extensive operational data spanning more than 5.4 billion square feet of turf mowed, 68,000+ hours of autonomous mowing and more than 50,000 operator days, the equivalent of 265 mowing seasons.

“Greenzie is helping define safety in autonomous landscape operations, and transparency is a critical part of that,” said Steve Bush, chief operating officer of Greenzie. “These results show that commercial autonomy is operating safely at meaningful scale in the field. Transparency matters because as this category matures, real-world data helps build confidence in what responsible deployment looks like.”

The report’s findings are particularly significant in the context of the U.S. landscaping industry, which employs roughly 1.3 million workers and experiences a higher-than-average rate of workplace accidents compared to other fields. Greenzie’s multi-year operating data shows that autonomy is not theoretical; it is already being deployed consistently and performing safely at scale.

“Greenzie Powered Autonomy™ has been validated through years of sustained use in the field,” Bush said. “That level of real-world performance reinforces both the reliability of our platform and the broader readiness of commercial autonomy.”

Greenzie attributes this performance to a disciplined safety approach that includes robust perception, tested operating standards and continuous validation in real-world commercial environments.

For more information about Greenzie, visit greenzie.com.

About Greenzie

Founded in 2018, Greenzie is the technology platform powering commercial autonomy. Created to solve the landscape industry’s labor and productivity challenges, Greenzie works with leading equipment manufacturers to deliver the software, navigation and safety systems that enable mowing and other outdoor power equipment to operate autonomously in real-world commercial environments. Today, Greenzie’s platform is running on hundreds of machines in active use, helping manufacturers bring autonomy to market and allowing operators to get more done with limited labor—moving autonomy from early experimentation to everyday operations. For more information, visit greenzie.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/greenzie-releases-2025-annual-safety-report-documenting-multi-year-safety-performance-at-commercial-scale-302750335.html

SOURCE Greenzie

Continue Reading

Technology

CGI renews global SAP S/4HANA operations and SAP BTP operations certifications, reinforcing its consistent, quality delivery at scale

Published

on

By

Stock Market Symbols
GIB.A (TSX)
GIB (NYSE)
cgi.com/newsroom

MONTRÉAL, April 23, 2026 /CNW/ – CGI (NYSE: GIB) (TSX: GIB.A), one of the largest independent IT and business consulting services firms in the world, announced that it has achieved the following recertifications for its global operation capabilities:

SAP S/4HANA operations and works with RISE with SAP SAP BTP operations and works with RISE with SAP

These recertifications highlight CGI’s ability to deliver consistent, high-quality managed SAP services and operations across regions, including services aligned with RISE with SAP. CGI’s SAP-based services help clients reduce operational risk, improve performance and efficiency and scale transformation with greater predictability. This also builds on CGI’s SAP alliance relationship momentum, including its recent AWS SAP Competency Partner status which highlights CGI’s expertise in modernizing mission-critical SAP workloads with AI-enabled cloud solutions.

“Running SAP at enterprise scale requires a partner with proven capabilities, delivery discipline and the ability to innovate securely, including through the integration of AI to deliver tangible outcomes,” said Didier Thérond, President, CGI France operations, and Global Executive Sponsor for CGI’s partnership with SAP. “These global recertifications reinforce CGI’s end-to-end SAP capabilities, including AI-enabled services, helping clients operate mission-critical systems with confidence and advance their modernization and cloud strategies.”

“CGI remains a trusted partner in our SAP Operations Partner program, consistently demonstrating a structured and disciplined approach to certification,” said Rudolf Scheipers, VP, Head of SAP Operations Partner Certification, SAP Partner Innovation Lifecycle Services. “These recertifications highlight the company’s mature operating model and commitment to the high standards we expect globally, ensuring clients running SAP environments can rely on consistent, secure, and efficient operations.”

CGI’s global alliance strategy features partnerships with more than 150 technology companies and supports its local relationship model complemented by a global delivery network. Through its SAP alliance, CGI helps organizations accelerate innovation, deploy and manage SAP solutions globally, and deliver industry-specific business outcomes with rapid, scalable, and AI-enabled cloud and ERP services.

About CGI
Founded in 1976, CGI is among the largest independent IT and business consulting services firms in the world. With 94,000 consultants and professionals across the globe, CGI delivers an end-to-end portfolio of capabilities, from strategic IT and business consulting to systems integration, managed IT and business process services and intellectual property solutions. CGI works with clients through a local relationship model complemented by a global delivery network that helps clients digitally transform their organizations and accelerate results. CGI Fiscal 2025 reported revenue is CA$15.91 billion and CGI shares are listed on the TSX (GIB.A) and the NYSE (GIB). Learn more at cgi.com.

View original content:https://www.prnewswire.com/news-releases/cgi-renews-global-sap-s4hana-operations-and-sap-btp-operations-certifications-reinforcing-its-consistent-quality-delivery-at-scale-302750863.html

SOURCE CGI Inc.

Continue Reading

Technology

Scholastic Corporation Announces Final Results of Modified Dutch Auction Tender Offer

Published

on

By

NEW YORK, April 23, 2026 /PRNewswire/ — Scholastic Corporation (the “Company” or “Scholastic”) (Nasdaq: SCHL), the global children’s publishing, education and media company, today announced the final results of its “modified Dutch Auction” tender offer for shares of its common stock, which expired at 5:00 p.m., New York City time, on April 20, 2026.

Based on the final count by Computershare Trust Company, N.A., the depositary for the tender offer, a total of 2,834,018 shares of Scholastic’s common stock, par value $0.01 per share (each share of Scholastic’s common stock, a “Share,” and collectively, “Shares”), were properly tendered and not properly withdrawn at or below the purchase price of $40.00 per Share, including 989,343 Shares that were tendered by notice of guaranteed delivery.

Scholastic has accepted for purchase a total of 2,834,018 Shares through the tender offer at a price of $40.00 per Share, for an aggregate cost of $113,360,720.00, excluding fees and expenses relating to the tender offer.  The total of 2,834,018 Shares that Scholastic has accepted for purchase represents approximately 13.7% of the total number of Shares outstanding as of April 19,  2026.

J.P. Morgan Securities LLC served as the dealer manager for the tender offer. Georgeson LLC served as the information agent. Holders of common stock who have questions or need information about the tender offer may call Georgeson LLC at (866) 539-9980 (toll free). Banks and brokers may call Georgeson at (866) 539-9980 or J.P. Morgan Securities LLC at (877) 371-5947 (toll free).

About Scholastic 

For more than 100 years, Scholastic Corporation (Nasdaq: SCHL) has been meeting children where they are – at school, at home and in their communities – by creating quality content and experiences, all beginning with literacy. Scholastic delivers stories, characters, and learning moments that empower all kids to become lifelong readers and learners through bestselling children’s books, literacy- and knowledge-building resources for schools including classroom magazines, and award-winning, entertaining children’s media. As the world’s largest publisher and distributor of children’s books through school-based book clubs and book fairs, classroom libraries, school and public libraries, retail, and online, and with a global reach into more than 135 countries, Scholastic encourages the personal and intellectual growth of all children, while nurturing a lifelong relationship with reading, themselves, and the world around them. Learn more at www.scholastic.com.

Forward-Looking Statements

This news release contains certain forward-looking statements. Such forward-looking statements are subject to various risks and uncertainties, including the conditions of the children’s book and educational materials markets generally and acceptance of the Company’s products within those markets, and other risks and factors identified from time to time in the Company’s filings with the Securities and Exchange Commission. Actual results could differ materially from those currently anticipated.

SCHL: Financial

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/scholastic-corporation-announces-final-results-of-modified-dutch-auction-tender-offer-302751142.html

SOURCE Scholastic Corporation

Continue Reading

Trending